Cempra (CEMP) PT Slashed to $2 at Baird Amid CRL
Get Alerts CEMP Hot Sheet
Rating Summary:
1 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Baird analyst Brian Skorney reiterated an Underperform rating and slashed his price target on Cempra, Inc. (NASDAQ: CEMP) to $2.00 (from $6.00) following the FDA CRL.
Skorney commented, "With back-to-back PDUFA dates of the 27th/28th for oral/IV formulations of solithromycin, Cempra finally announced this morning that the FDA has rejected both NDAs, not just for manufacturing issues, but also due to concerns over liver toxicity. The FDA has requested a 9,000-patient study in order to adequately characterize the risk of liver tox. The cost of such a study, combined with what would likely still be prohibitive labeling, is so burdensome, we're lowering our price target to $2/share."
For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.
Shares of Cempra, Inc. closed at $6.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific (BSX) PT Raised to $83 at Stifel
- Owens Corning (OC) PT Raised to $172 at Evercore ISI
- UBS Downgrades Hino Motors Ltd. (7205:JP) (HINOY) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDA, Trader TalkRelated Entities
Robert W Baird, PDUFA, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!